Alpha-blocker therapy does not decrease the risk for prostate cancer death, but it is associated with an elevated risk for low-grade prostate cancer. Preclinical studies have suggested that ...

Fusion Pharmaceuticals (FUSN) is advancing a candidate which it acquired in February of 2023. It was acquired as an ongoing phase 2 study, known as the TATCIST trial. This is evaluating the use of FPI ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ...

Vancouver, British Columbia, Canada (Embargoed until 3:15 p.m. PDT, Saturday, June 11, 2022)—A novel targeted radionuclide alpha therapy for metastatic castration-resistant prostate cancer— 225 ...

Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments - ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...

Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...

Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer Following investigational new ...

JERUSALEM, June 22, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the first ...